Karnofsky is a standard way of measuring the ability of cancer patients to perform ordinary tasks. Patients reported a baseline Karnofsky score, showing their ability to engage in minimum daily living activities.

The Verthermia® team conducted an FDA Phase 1 clinical trial during 2014-2015, resulting in significant findings on the positive impact of the HEATT® (formally VV-PISH) procedure. These findings indicated improved survival rates and the ability to engage in daily living activities. Most of the patients enrolled in the study were in hospice or had advanced unresponsive cancer and completed at least one cycle of HEATT®.